Development of quantitative HPTLC-densitometry methods following a model approach for transfer of TLC screening methods for pharmaceutical products of atenolol, chloramphenicol, furosemide, glibenclamide, penicillin V potassium, and praziquantel. Issue 6 (3rd April 2018)

• Record Type: Journal Article
• Authors: Zeng, Bingsong; Nguyen, Kaitlin; Sherma, Joseph
• Is Part Of: Journal of liquid chromatography & related technologies. Volume 41:Issue 6(2018)
• Page Start: 324
• Page End: 328
• Publication Date: 2018-04-03
• Subjects: Amitriptyline HCL -- amodiaquine -- atenolol -- chloramphenicol -- diphenhydramine HCL -- furosemide -- glibenclamide -- mebendazole -- model process for tlc to quantitative hptlc transfer -- penicillin V potassium -- praziquantel -- thin-layer chromatography; Liquid chromatography -- Periodicals; Chromatographic analysis -- Periodicals; Separation (Technology) -- Periodicals; Biotechnology -- Periodicals; Chromatography, Liquid -- Periodicals; 543.8405
• DOI: 10.1080/10826076.2018.1448689
• Languages: English
• ISSNs: 1082-6076

Abstract

ABSTRACT: Transfer of six thin-layer chromatography (TLC) Global Pharma Health Fund E.V. Minilab manual protocols for detecting fake drugs in pharmaceutical products to quantitative high-performance TLC (HPTLC)-densitometry methods was performed following a previously published model process. The developed and validated methods for tablets or capsules containing atenolol, chloramphenicol, furosemide, glibenclamide, penicillin V potassium, and praziquantel involved use of a limited list of inexpensive, relatively nontoxic, readily available solvents and other reagents; silica gel 60 F254 plates; automated bandwise sample and standard solution application; ascending mobile phase development of plates in a chamber; and automated slit scanning densitometry for detection, identification, and quantification. Validation data for methods developed in an early version of the transfer model process that did not include standard addition validation are reported for pharmaceutical products containing amitriptyline HCl, amodiaquine, diphenhydramine HCl, and mebendazole. GRAPHICAL ABSTRACT: